Aiming to uproot the market for asthma attacks, AstraZeneca and Avillion tout two PhIII wins for inhaled combo drug

A collaboration launched in 2018 between AstraZeneca and British company Avillion is bearing new fruit Thursday for a severe asthma program.

The AstraZeneca and Avillion candidate, dubbed PT027, met all primary endpoints in two Phase III studies, the companies announced Thursday. A combination of the short-acting beta2-agonist (SABA) albuterol — a common asthma medication — and the inhaled corticosteroid budesonide, PT027 is positioned to become the new standard of care for asthma rescue therapy, AstraZeneca senior VP for respiratory and immunology Mina Makar told Endpoints News.